Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17 beta-estradiol for hormonal replacement therapy in women with surgical menopause
N. Mendoza et al., Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17 beta-estradiol for hormonal replacement therapy in women with surgical menopause, MATURITAS, 37(1), 2000, pp. 37-43
Citations number
20
Categorie Soggetti
Reproductive Medicine","Medical Research General Topics
Objective: To compare the effectiveness of tibolone and 17 beta -estradiol
on climacteric symptoms, lipid and biochemical parameters in women with sur
gical menopause, Methods: In a prospective randomised clinical trial group
comparative study, the effects on the aforementioned parameters, as well as
treatment compliance and side effects were studied with oral tibolone 2.5
mg per day and with transdermic 17 beta -estradiol at 50 mug per day for a
period of 12 months. Statistical analysis was carried out using the Fisher-
test, analysis of the variance (ANOVA) for the two factors and the Bouferon
i test. Results: Lipid metabolism analysis showed lower levels of HDL and t
riglycerides in the tibolone group. Other biochemical parameters were not a
ffected. Similar reductions in climacteric symptoms were found in both the
groups, but the tibolone group revealed a greater improvement in psychologi
cal problems and in sexual behaviour. No differences were observed with res
pect to compliance and side effects. Conclusions: Tibolone is as effective
or more than 17 beta -estradiol in reducing climacteric symptoms, and shows
greater triglyceride and total cholesterol improvements. Tibolone is a goo
d alternative to estrogens in women with surgical menopause. (C) 2000 Elsev
ier Science Ireland Ltd. All rights reserved.